• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
A2 - 2013 CADTH Symposium Personalized Medicines - Meulien - Salon C

A2 - 2013 CADTH Symposium Personalized Medicines - Meulien - Salon C






Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds


Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    A2 - 2013 CADTH Symposium Personalized Medicines - Meulien - Salon C A2 - 2013 CADTH Symposium Personalized Medicines - Meulien - Salon C Presentation Transcript

    • 2013 CADTH SymposiumPersonalized MedicinesPierre Meulien, President and CEOGenome CanadaMay 6, 2013St. John’s, NL
    • The Heart of Canada’s Genomics EnterpriseThe MetabolomicsInnovation CentreU. Vic./Genome BCProteomics CentreVancouverTorontoMontrealVictoriaGenomics InnovationCentre at the BCCA GSCEdmontonThe Centre forApplied GenomicsB.C.AlbertaPrairieGenomeCanadaOntarioAtlanticMcGill University &Genome QuebecInnovation Centre• 6 Regional Genome Centres• 5 Science and TechnologyInnovation Centres• 160+ Genomics Projects• $2 Billion Investment• 7 Key Economic Sectors:Agriculture, Energy, Environment,Fisheries, Forestry, Health andMiningQuébec
    • Sequencing Genomes is truly disruptive• Technology that has – over the past 10 years-decreased in cost by 1 million fold• Is perturbing the status quo as reflected by many,many questions being askedWhat can your genome tell you about your healthstatus?What can it tell you about your health future?Who owns your genome data?Who has access to it?How will it be used?• Will require massive change to an already stressedsystem if we want genomics to be part of personalhealth records
    • Personalized MedicineSpectrum of Genetic Contribution to DiseaseVery rare single genedisordersMore common singlegene disorders• Cystic Fibrosis• Hemophilia• Huntington’s Disease• Muscular DystrophyDisorders with prominentgenetic contribution• Childhood cancer• BRCA 1/2 Breast cancer• Some forms of autismspectrum disorders• Adverse drug reactionsGenetic susceptibility tocertain common diseases• Colon cancer• Certain cardiovasculardiseases• Certain forms of AlzheimerMost commonchronic diseaseswith many geneticfactors but alsomajorenvironmentalfactors contributingto disease onset
    • So how do we translate when we need toconsider a lot of complex issues?• How good is the technology? (clinical validation)• In a fast moving field, when do we decide that “now isthe time for transfer”• Is it easy to adapt existing clinical laboratorystructures?• Who will be making these decisions? (and based onwhat criteria?)• Technology assessment based on sound economicsand clinical benefit?• Who will pay?• How can behavioural change be accelerated
    • What we need to know• Demonstrations that the technology candeliver real value to patients• Demonstrations that integrating thetechnology within the healthcare system willbe cost effective
    • How many human single gene disorders remain to be discovered?Single‐gene disordersgene known~2900gene unknown~3600suspected single genedisorders~4500300 DisordersProposed
    • 2012 Large-Scale Applied ResearchProject CompetitionGenomics and Personalized Health• Program partnered with the Canadian Institutes of HealthResearch• $71 Million of federal money more than doubled throughpartnerships for a total of $150• Required teams to provide an economic analysis and rationalefor why their particular application will demonstrate value tothe health system• Required relevant Economic, Environmental, Ethical, Legal andSocial (GE3LS) research• Teams were requested to provide detailed development planfor integration into the HC system• Teams had to have buy-in from the payer and clinicians andmust have considered the regulatory frameworks existing inCanada• 17 projects funded – announced – March 26th.
    • Some examples of approved projectsIncreasing effectiveness of drugs, lowering adverse drugreactions and/or defining intervention strategies bystratifying patients according to molecular profiles Epilepsy Autism Lymphoma, Breast Cancer, Glioblastoma, andother cancers Rare diseases Stroke HIV Inflammatory Bowel Disease Cardiovascular
    • Integration of Genomics intothe Healthcare System• Develop receptor capacity for technology pull (capacity forclinical and translational research)• Involvement of the private sector• Educate and train healthcare professionals to be proficientusers of the technology• Ensure information systems are modern and harmonize e-patient records• Role of patients and advocacy groups in demanding evidencebased medicine• Robust technology assessments focused on improvement onclinical outcomes and economic benefit analyses• More balance between prevention and treatment• Legislation to “encourage” behaviour change in the youngerpopulation
    • 150 rue Metcalfe Street, Suite 2100Ottawa, OntarioCANADA K2P 1P1Tel. : 613-751-4460info@genomecanada.cawww.genomecanada.ca